Prospect: information for the patient
Zolmitriptán Flas Sandoz 2.5 mg buccal dispersible tablets EFG
Zolmitriptán Flas Sandoz 5 mg buccal dispersible tablets EFG
Read this prospect carefully before starting to take this medicine, as it contains important information for you.
-Keep this prospect as you may need to read it again.
-If you have any doubts, consult your doctor or pharmacist.
-This medicine has been prescribed only for you and should not be given to other people, even if they have the same symptoms as you, as it may harm them.
-If you experience any adverse effects, consult your doctor or pharmacist, even if they are not listed in this prospect. See section 4.
1.What is Zolmitriptán Flas Sandoz and what it is used for
2.What you need to know before starting to take Zolmitriptán Flas Sandoz
3.How to take Zolmitriptán Flas Sandoz
4.Possible adverse effects
5.Storage of Zolmitriptán Flas Sandoz
6.Contents of the package and additional information
Zolmitriptán Flas Sandoz contains the active ingredient called zolmitriptan and belongs to a group of medicines called triptans.
Zolmitriptanis used to treat migraine headaches in adults aged 18 years and older.
Do not take Zolmitriptán Flas Sandoz if:
Consult your doctor or pharmacist before starting to take zolmitriptán if you have:
Inform your doctor if you are taking any medication for depression or herbal supplements such as St. John's Wort (Hypericum perforatum) (for more information, see section “Other medications and Zolmitriptán Flas Sandoz”.
Zolmitriptán may increase blood pressure. If blood pressure becomes too high, you may experience symptoms such as headache, dizziness, or ringing in the ears. If this occurs, contact your doctor.
If you take zolmitriptán too frequently, you may experience chronic headache. In this case, contact your doctor, as it may be necessary to discontinue this medication.
Inform your doctor or pharmacist of your symptoms. Your doctor will indicate if you have migraines.You should only take zolmitriptán for a migraine attack.Do not use zolmitriptán to treat headaches that may be caused by other more serious diseases.
Zolmitriptán Flas Sandoz is not recommended for people over 65 years old. If you are over 65 years old, your doctor will indicate if you can take these tablets.
Children and adolescents
Zolmitriptán Flas Sandoz is not recommended for people under 18 years old.
Inform your doctor or pharmacist if you are taking, have taken recently, or may need to take any other medication.
DO NOT TAKE Zolmitriptán Flas Sandoz with other medications for migraine,such as:
If you take other triptans different from zolmitriptán, leave 24 hours before taking Zolmitriptán Flas Sandoz.
After taking zolmitriptán, leave 24 hours before taking other triptans different from Zolmitriptán Flas Sandoz,
Consult with your doctor the administration instructions of the medication and the risks of taking these tablets with:
If you are pregnant, or in the lactation period, consult your doctor before taking any other medication. If you are pregnant, you will only be able to take zolmitriptán if your doctor determines it is necessary.
If you are in the lactation period, consult with your doctor before taking this medication. You should avoid breastfeeding for 24 hours after taking zolmitriptán.
Migraine itself or treatment with zolmitriptán may cause drowsiness in some patients. There have also been reports of dizziness in some patients treated with this medication. If you experience these effects, you should monitor your ability to drive vehicles or operate machinery.
This medication contains less than 23 mg of sodium (1 mmol) per buccal tablet; this is essentially “sodium-free”.
Sulfites may cause rare but severe allergic reactions and bronchospasm (sudden feeling of suffocation).
Zolmitriptán Flas Sandoz 2.5 mg buccal tablets EFG
This medication contains 2.5 mg of aspartame in each buccal tablet. Aspartame contains a source of phenylalanine that may be harmful in cases of phenylketonuria (PKU), a rare genetic disorder in which phenylalanine accumulates because the body is unable to eliminate it correctly.
Zolmitriptán Flas Sandoz 5 mg buccal tablets EFG
This medication contains 5 mg of aspartame in each buccal tablet. Aspartame contains a source of phenylalanine that may be harmful in cases of phenylketonuria (PKU), a rare genetic disorder in which phenylalanine accumulates because the body is unable to eliminate it correctly.
Follow exactly the administration instructions for this medication as indicated by your doctor or pharmacist. If in doubt, consult your doctor or pharmacist again.
You can take Zolmitriptán Flas Sandoz as soon as a migraine headache begins. You can also take it once a headache has started.
The recommended doseis 2.5 mg.
Your doctor will tell you the most suitable dose for your case and it is essential that you take the medication as your doctor has instructed you.
Most migraine attacks are relieved with a single dose (one tablet) of zolmitriptán,but if not, DO NOT take a second tablet to treat the same attack as the likelihood of it being effective is low.
Consult your doctor if the tablets do not produce sufficient efficacy against your migraine. Your doctor may increase the dose up to 5 mg or change the treatment.
If you experience ANOTHER migraine attack within the first 24 hours after the first one, you can take a new tablet of zolmitriptán, but never take more than two tablets in 24 hours.
If you have been prescribed the 2.5 mg tablet, the maximum daily dose is 5 mg.
If you have been prescribed the 5 mg tablet, the maximum daily dose is 10 mg.
In either case, you must wait at least 2 hours between doses.
Administration Form
Take the buccal tablets in the following way:
You can take Zolmitriptán Flas Sandoz with or without food. This does not affect how zolmitriptán works.
If you take more Zolmitriptán Flas Sandoz than you should
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service, phone: 91 562 04 20, indicating the medication and the amount ingested.
If you have any other questions about the use of this medication, ask your doctor or pharmacist.
Like all medicines, this medicine may cause side effects, although not everyone will experience them.
If you experience any of the following side effects, stop taking the medicine and consult your doctor immediately.
Severe rare side effects (may affect up to 1 in 1,000 people):
Very rare severe side effects (may affect up to 1 in 10,000 people)):
Other possible side effects
Frequent:may affect up to 1 in 10 people.
Infrequent:may affect up to 1 in 100 people.
Rare::may affect up to 1 in 1,000 people.
Very rare:may affect up to 1 in 10,000 people.
As with other medicines in this group, there have been rare cases of heart attacks and strokes reported, most of which occurred in patients with risk factors for heart and blood vessel diseases (high blood pressure, diabetes, smokers, family history of heart disease or stroke).
If you consider any of the side effects you are experiencing to be severe or if you notice any side effect not mentioned in this leaflet, inform your doctor or pharmacist.
Reporting side effects
If you experience any type of side effect, consult your doctor or pharmacist, even if it is a possible side effect not listed in this leaflet. You can also report them directly through the Spanish System for the Pharmacovigilance of Medicines for Human Use: https://www.notificaram.es. By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the packaging and the blister, after CAD/EXP. The expiration date is the last day of the month indicated.
Store in the original packaging to protect from moisture.
Medications should not be disposed of through drains or trash. Dispose of the packaging and medications you no longer need at the SIGRE collection point at the pharmacy. If in doubt, ask your pharmacist how to dispose of unused packaging and medications. By doing so, you will help protect the environment.
Composition of Zolmitriptan Flas Sandoz
Zolmitriptan Flas Sandoz 2.5 mg orally disintegrating tablets EFG
Each orally disintegrating tablet contains 2.5 mg of zolmitriptan.
Zolmitriptan Flas Sandoz 5 mg orally disintegrating tablets EFG
Each orally disintegrating tablet contains 5 mg of zolmitriptan.
Appearance of the product and contents of the package
Zolmitriptan Flas Sandoz 2.5 mg orally disintegrating tablets EFG
Orally disintegrating tablets, white, round, flat, and with the inscription “ZMT 2.5” on one face.
Zolmitriptan Flas Sandoz 5 mg orally disintegrating tablets EFG
Orally disintegrating tablets, white, round, flat, and with the inscription “ZMT 5” on one face.
The orally disintegrating tablets are packaged in Alu/Alu blisters, inserted into a cardboard package.
Zolmitriptan 2.5 mg orally disintegrating tablets
Package sizes:2, 3, 4, 6, 10, 12, 18, or 24 orally disintegrating tablets.
Zolmitriptan 5 mg orally disintegrating tablets
Package sizes:2, 3, 4, 6, 12, 18, or 24 orally disintegrating tablets.
Only some package sizes may be marketed.
Holder of the marketing authorization and responsible for manufacturing
Holder of the marketing authorization:
Sandoz Farmacéutica, S.A.
Centro Empresarial Parque Norte
Edificio Roble
C/ Serrano Galvache, 56
28033 Madrid
Spain
Responsible for manufacturing:
Salutas Pharma GmbH
Otto-von-Guericke-Allee 1,
39179 Barleben
Germany
Salutas Pharma GmbH
Dieselstrasse 5, 70839 Gerlingen
Germany
or
Lek Pharmaceuticals d.d.
Verovškova 57,
1526 Ljubljana
Slovenia
or
Lek Pharmaceuticals d.d.
Trimlini 2D, 9220
Lendava
Slovenia
or
Lek S.A.
Ul. Domaniewska 50 C,
02-672 Warsaw
Poland
or
S.C. Sandoz, S.R.L.
Str. Livezeni nr. 7A,
RO-540472 Targu-Mures
Romania
This medicine is authorized in the member states of the European Economic Area with the following names:
Belgium | Zolmitriptan Sandoz 2.5 mg, orodispergeerbare tabletten |
Finland | Zolmitriptan Sandoz 2.5 mg suussa hajoava tabletti |
France | ZOLMITRIPTAN SANDOZ 2.5 mg, comprimé orodispersible |
Norway | Zolmitriptan Sandoz 2.5 mg smeltetablett |
Netherlands | Zolmitriptan Sandoz smelttablet 2.5 mg, orodispergeerbare tabletten Zolmitriptan Sandoz smelttablet 5 mg, orodispergeerbare tabletten |
Date of the last review of this leaflet:October 2021.
Detailed and updated information on this medicine is available on the website of the Spanish Agency for Medicines and Medical Devices (AEMPS)http://www.aemps.gob.es/
Have questions about this medication or your symptoms? Connect with a licensed doctor for guidance and personalized care.